HepaLife Technologies Inc. Achieves Major Milestone in Development of Artificial Liver Device

BOSTON--(BUSINESS WIRE)--HepaLife Technologies, Inc. (OTCBB:HPLF) (FWB:HL1) (WKN:500625), developing the first-of-its-kind artificial liver device, today announced favorable early test results of the Company’s proprietary bioreactor system, the main mechanical component of an artificial liver device, which successfully replicated the human liver’s key function – removal of toxic ammonia and synthesis of urea.